Share on StockTwits

Tornier NV (NASDAQ:TRNX) was upgraded by equities researchers at BMO Capital Markets from a “market perform” rating to an “outperform” rating in a research report issued on Friday, TheFlyOnTheWall.com reports. The firm currently has a $24.00 price objective on the stock, up from their previous price objective of $20.00. BMO Capital Markets’ price objective would suggest a potential upside of 10.45% from the company’s current price.

Shares of Tornier NV (NASDAQ:TRNX) traded up 11.49% during mid-day trading on Friday, hitting $21.73. The stock had a trading volume of 541,015 shares. Tornier NV has a 1-year low of $15.17 and a 1-year high of $24.35. The stock has a 50-day moving average of $22.24 and a 200-day moving average of $20.52. The company’s market cap is $1.060 billion.

Tornier NV (NASDAQ:TRNX) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.16) by $0.04. The company had revenue of $86.85 million for the quarter, compared to the consensus estimate of $79.40 million. During the same quarter last year, the company posted ($0.28) earnings per share. Tornier NV’s revenue was up 11.2% compared to the same quarter last year. On average, analysts predict that Tornier NV will post $-0.54 earnings per share for the current fiscal year.

A number of other analysts have also recently weighed in on TRNX. Analysts at TheStreet upgraded shares of Tornier NV from a “sell” rating to a “hold” rating in a research note on Friday, June 6th. Analysts at Barclays raised their price target on shares of Tornier NV from $23.00 to $26.00 in a research note on Thursday, June 5th. They now have an “overweight” rating on the stock. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $22.67.

Tornier N.V. (NASDAQ:TRNX) is a global medical device company focused on surgeons that treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.